{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T03:29:06Z","timestamp":1789874946957,"version":"4.0.1"},"reference-count":27,"publisher":"Becaris Publishing Limited","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are common types of non-Hodgkin's lymphoma, and real-world evidence continues to be lacking for healthcare costs and utilization among DLBCL and FL patients. Our study aims to describe medical and pharmacy costs and health resource utilization and to characterize longitudinal treatment patterns among these patients.\n            <jats:bold>Methods:<\/jats:bold>\n            A retrospective observational study was performed among adult patients with DLBCL or FL using the US MarketScan (Truven) administrative claims data from 1 January\u00a02007 to 31 December\u00a02015. Diagnoses of DLBCL and FL were based upon ICD-9 codes. Identifications of treatment lines involved 30 lymphoma-specific anticancer systemic agents. Direct healthcare costs and utilizations were computed in the 1-year postdiagnosis period. Generalized linear models with a gamma link were used to compare healthcare costs between therapies with and without rituximab.\n            <jats:bold>Results:<\/jats:bold>\n            A total of 2767 DLBCL and 5989 FL patients received frontline therapy. The majority received treatment within 3 months after initial diagnosis (DLBCL 79.9% and FL 62.4%) and were treated with rituximab or bendamustine either alone or in combination (DLBCL 67.4% and FL 84.7%). The total healthcare costs were US $15,555 and $10,192 per patient per month within 1 year following their initial diagnosis for DLBCL and FL, respectively. The medical costs were nearly twice as much as the drug costs for DLBCL patients. Both DLBCL and FL patients receiving rituximab had higher pharmacy costs but lower medical costs (p\u00a0&lt;\u00a00.001). During the first year following initial diagnosis, the resource utilization (per patient per month) of DLBCL patients included 0.21 inpatient admissions, 0.26 radiation therapy, 2.63 outpatient or office visits, 0.18 emergency room visits, 0.06 intensive care unit admissions and 0.10 stem cell transplantation. FL patients occupied less health resources than DLBCL patients.\n            <jats:bold>Conclusion:<\/jats:bold>\n            The healthcare costs and health resources utilized were considerable in non-Hodgkin's lymphoma, especially DLBCL patients.\n          <\/jats:p>","DOI":"10.2217\/cer-2018-0094","type":"journal-article","created":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T14:23:23Z","timestamp":1552314203000},"page":"393-402","source":"Crossref","is-referenced-by-count":30,"title":["Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA"],"prefix":"10.57264","volume":"8","author":[{"given":"Jinma","family":"Ren","sequence":"first","affiliation":[{"name":"Center for Outcomes Research, Department of Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl V","family":"Asche","sequence":"additional","affiliation":[{"name":"Center for Outcomes Research, Department of Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL, USA"},{"name":"Center for Pharmacoepidemiology &amp; Pharmacoeconomic Research, University of Illinois at Chicago College of Pharmacy, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Shou","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Galaznik","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"key":"e_1_3_3_3_2","unstructured":"Cancer Statistics Center Americal Cancer Society\n                                        . \n                                        2017 estimates\n                                         (\n                                        2017\n                                        ). \n                                        https:\/\/cancerstatisticscenter.cancer.org\/#\/\n                                        ."},{"issue":"8","key":"e_1_3_3_4_2","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1080\/10428190600573325","article-title":"Medical costs associated with non-Hodgkin's lymphoma in the United States during the first two years of treatment","volume":"47","author":"Kutikova L","year":"2006","unstructured":"Kutikova L , Bowman L , Chang S , Long SR , Arning M , Crown WH . Medical costs associated with non-Hodgkin's lymphoma in the United States during the first two years of treatment . Leuk. Lymphoma 47 ( 8 ), 1535 \u2013 1544 ( 2006 ).","journal-title":"Leuk. Lymphoma"},{"issue":"8","key":"e_1_3_3_5_2","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2165\/11314820-000000000-00000","article-title":"Economic burden of follicular non-Hodgkin's lymphoma","volume":"27","author":"Foster T","year":"2009","unstructured":"Foster T , Miller JD , Boye ME , Russell MW . Economic burden of follicular non-Hodgkin's lymphoma . Pharmacoeconomics 27 ( 8 ), 657 \u2013 679 ( 2009 ).","journal-title":"Pharmacoeconomics"},{"key":"e_1_3_3_6_2","unstructured":"American Cancer Society\n                                        . \n                                        Types of non-Hodgkin lymphoma\n                                         (\n                                        2017\n                                        ). \n                                        www.cancer.org\/cancer\/non-hodgkin-lymphoma\/about\/types-of-non-hodgkin-lymphoma.html\n                                        ."},{"issue":"4","key":"e_1_3_3_7_2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier B","year":"2002","unstructured":"Coiffier B , Lepage E , Briere J CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma . N. Engl. J. Med. 346 ( 4 ), 235 \u2013 242 ( 2002 ).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_3_8_2","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1182\/asheducation-2011.1.498","article-title":"Relapsed\/refractory diffuse large B-cell lymphoma","volume":"2011","author":"Friedberg JW","year":"2011","unstructured":"Friedberg JW . Relapsed\/refractory diffuse large B-cell lymphoma . Hematol. Am. Soc. Hematol. Educ. Program 2011 , 498 \u2013 505 ( 2011 ).","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"issue":"3","key":"e_1_3_3_9_2","doi-asserted-by":"crossref","first-page":"a001719","DOI":"10.1101\/mcs.a001719","article-title":"Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?","volume":"3","author":"Amin AD","year":"2017","unstructured":"Amin AD , Peters TL , Li L Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer? Cold Spring Harb. Mol. Case Stud. 3 ( 3 ), a001719 ( 2017 ).","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"issue":"1","key":"e_1_3_3_10_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.beha.2004.06.002","article-title":"The clinical course of follicular lymphoma","volume":"18","author":"Rohatiner AZ","year":"2005","unstructured":"Rohatiner AZ , Lister TA . The clinical course of follicular lymphoma . Best Pract. Res. Clin. Hematol. 18 ( 1 ), 1 \u2013 10 ( 2005 ).","journal-title":"Best Pract. Res. Clin. Hematol."},{"issue":"10","key":"e_1_3_3_11_2","first-page":"E57","article-title":"Follicular lymphoma: a therapeutic update","volume":"92","author":"Italiano A","year":"2005","unstructured":"Italiano A , Thyss A . Follicular lymphoma: a therapeutic update . Bull. Cancer 92 ( 10 ), E57 \u2013 E64 ( 2005 ).","journal-title":"Bull. Cancer"},{"issue":"11","key":"e_1_3_3_12_2","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1093\/annonc\/mdv376","article-title":"Life expectancy of young adults with follicular lymphoma","volume":"26","author":"Conconi A","year":"2015","unstructured":"Conconi A , Lobetti-Bodoni C , Montoto S Life expectancy of young adults with follicular lymphoma . Ann. Oncol. 26 ( 11 ), 2317 \u2013 2322 ( 2015 ).","journal-title":"Ann. Oncol."},{"issue":"12","key":"e_1_3_3_13_2","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1007\/s12094-015-1437-1","article-title":"SEOM clinical guidelines for the treatment of follicular non-Hodgkin's lymphoma","volume":"17","author":"Provencio Pulla M","year":"2015","unstructured":"Provencio Pulla M , Alfaro Lizaso J , De La Cruz Merino L SEOM clinical guidelines for the treatment of follicular non-Hodgkin's lymphoma . Clin. Transl. Oncol. 17 ( 12 ), 1014 \u2013 1019 ( 2015 ).","journal-title":"Clin. Transl. Oncol."},{"issue":"5","key":"e_1_3_3_14_2","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1586\/erp.12.57","article-title":"Cost\u2013effectiveness of rituximab in follicular lymphoma","volume":"12","author":"Johnston KM","year":"2012","unstructured":"Johnston KM , Bolbocean C , Connors J , Peacock S . Cost\u2013effectiveness of rituximab in follicular lymphoma . Expert Rev. Pharmacoecon. Outcomes Res. 12 ( 5 ), 569 \u2013 577 ( 2012 ).","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"issue":"2","key":"e_1_3_3_15_2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jval.2014.12.017","article-title":"Comparing the cost\u2013effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma","volume":"18","author":"Chen Q","year":"2015","unstructured":"Chen Q , Ayer T , Nastoupil LJ , Rose AC , Flowers CR . Comparing the cost\u2013effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma . Value Health 18 ( 2 ), 189 \u2013 197 ( 2015 ).","journal-title":"Value Health"},{"key":"e_1_3_3_16_2","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1186\/1471-2407-14-586","article-title":"Real world costs and cost\u2013effectiveness of rituximab for diffuse large B-cell lymphoma patients: a population-based analysis","volume":"14","author":"Khor S","year":"2014","unstructured":"Khor S , Beca J , Krahn M Real world costs and cost\u2013effectiveness of rituximab for diffuse large B-cell lymphoma patients: a population-based analysis . BMC Cancer 14 , 586 ( 2014 ).","journal-title":"BMC Cancer"},{"issue":"24","key":"e_1_3_3_17_2","doi-asserted-by":"crossref","first-page":"6079","DOI":"10.1002\/cncr.27638","article-title":"Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma","volume":"118","author":"Griffiths RI","year":"2012","unstructured":"Griffiths RI , Gleeson ML , Mikhael J , Dreyling MH , Danese MD . Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma . Cancer 118 ( 24 ), 6079 \u2013 6088 ( 2012 ).","journal-title":"Cancer"},{"issue":"3","key":"e_1_3_3_18_2","doi-asserted-by":"crossref","first-page":"e0174648","DOI":"10.1371\/journal.pone.0174648","article-title":"Rituximab maintenance therapy for patients with diffuse large B-cell lymphoma: a meta-analysis","volume":"12","author":"Zhou X","year":"2017","unstructured":"Zhou X , Ma T , Zhang Y , Zhou N , Li J . Rituximab maintenance therapy for patients with diffuse large B-cell lymphoma: a meta-analysis . PLoS ONE 12 ( 3 ), e0174648 ( 2017 ).","journal-title":"PLoS ONE"},{"issue":"5","key":"e_1_3_3_19_2","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/bjh.13652","article-title":"Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicenter randomized Phase III trial","volume":"171","author":"Witzens-Harig M","year":"2015","unstructured":"Witzens-Harig M , Benner A , McClanahan F Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicenter randomized Phase III trial . Brit. J. Hematol. 171 ( 5 ), 710 \u2013 719 ( 2015 ).","journal-title":"Brit. J. Hematol."},{"key":"e_1_3_3_20_2","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.1549","article-title":"Rituximab maintenance therapy of follicular lymphoma in clinical practice","author":"Duhrsen U","year":"2018","unstructured":"Duhrsen U , Broszeit-Luft S , Dieing A Rituximab maintenance therapy of follicular lymphoma in clinical practice . Cancer Med. DOI:10.1002\/cam4.1549 ( 2018 ) ( Epub ahead of print ).","journal-title":"Cancer Med."},{"issue":"6","key":"e_1_3_3_21_2","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1001\/jamaoncol.2018.0111","article-title":"Rituximab maintenance therapy after first-line induction chemoimmunotherapy for follicular lymphoma","volume":"4","author":"Hilal T","year":"2018","unstructured":"Hilal T , Leis JF , Reeder CB . Rituximab maintenance therapy after first-line induction chemoimmunotherapy for follicular lymphoma . JAMA Oncol. 4 ( 6 ), 859 \u2013 860 ( 2018 ).","journal-title":"JAMA Oncol."},{"issue":"2","key":"e_1_3_3_22_2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s12253-017-0234-2","article-title":"Efficacy and tolerability of a 2-year rituximab maintenance therapy in patients with advanced follicular lymphoma after induction of response with rituximab-containing first line-Regimens (HUSOM Study)","volume":"24","author":"Schneider T","year":"2018","unstructured":"Schneider T , Rosta A , Losonczy H Efficacy and tolerability of a 2-year rituximab maintenance therapy in patients with advanced follicular lymphoma after induction of response with rituximab-containing first line-Regimens (HUSOM Study) . Pathol. Oncol. Res. 24 ( 2 ), 199 \u2013 205 ( 2018 ).","journal-title":"Pathol. Oncol. Res."},{"issue":"2","key":"e_1_3_3_23_2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1185\/03007990802636817","article-title":"Cost\u2013effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States","volume":"25","author":"Lyman G","year":"2009","unstructured":"Lyman G , Lalla A , Barron R , Dubois RW . Cost\u2013effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States . Curr. Med. Res. Opin. 25 ( 2 ), 401 \u2013 411 ( 2009 ).","journal-title":"Curr. Med. Res. Opin."},{"key":"e_1_3_3_24_2","first-page":"1","article-title":"Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma","author":"Maziarz RT","year":"2017","unstructured":"Maziarz RT , Hao Y , Guerin A Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma . Leuk. Lymphoma DOI:10.1080\/10428194.2017.1375100 1 \u2013 10 ( 2017 ) ( Epub ahead of print ).","journal-title":"Leuk. Lymphoma"},{"issue":"8","key":"e_1_3_3_25_2","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.3109\/10428194.2015.1106537","article-title":"Incidence of intensive care unit admission, outcome and post intensive care survival in patients with diffuse large B-cell lymphoma","volume":"57","author":"Wohlfarth P","year":"2016","unstructured":"Wohlfarth P , Carlstrom A , Staudinger T Incidence of intensive care unit admission, outcome and post intensive care survival in patients with diffuse large B-cell lymphoma . Leuk. Lymphoma 57 ( 8 ), 1831 \u2013 1838 ( 2016 ).","journal-title":"Leuk. Lymphoma"},{"issue":"6","key":"e_1_3_3_26_2","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s12185-015-1874-1","article-title":"Efficacy and feasibility of autologous stem cell transplantation in patients with diffuse large B-cell lymphoma with secondary central nervous system involvement","volume":"102","author":"Lee MY","year":"2015","unstructured":"Lee MY , Kim HS , Lee JY Efficacy and feasibility of autologous stem cell transplantation in patients with diffuse large B-cell lymphoma with secondary central nervous system involvement . Int. J. Hematol. 102 ( 6 ), 678 \u2013 688 ( 2015 ).","journal-title":"Int. J. Hematol."},{"issue":"3","key":"e_1_3_3_27_2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/bmt.2015.286","article-title":"Autologous stem cell transplantation for relapsed\/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party","volume":"51","author":"Robinson SP","year":"2016","unstructured":"Robinson SP , Boumendil A , Finel H Autologous stem cell transplantation for relapsed\/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party . Bone Marrow Transplant. 51 ( 3 ), 365 \u2013 371 ( 2016 ).","journal-title":"Bone Marrow Transplant."},{"issue":"5","key":"e_1_3_3_28_2","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jgo.2015.04.005","article-title":"Autologous hematopoietic stem cell transplantation in elderly patients (>\/= 70 years) with non-Hodgkin's lymphoma: a French Society of Bone Marrow Transplantation and Cellular Therapy Retrospective Study","volume":"6","author":"Hermet E","year":"2015","unstructured":"Hermet E , Cabrespine A , Guieze R Autologous hematopoietic stem cell transplantation in elderly patients (>\/= 70 years) with non-Hodgkin's lymphoma: a French Society of Bone Marrow Transplantation and Cellular Therapy Retrospective Study . J. Geriatr. Oncol. 6 ( 5 ), 346 \u2013 352 ( 2015 ).","journal-title":"J. Geriatr. Oncol."},{"issue":"1","key":"e_1_3_3_29_2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/jnci\/djr450","article-title":"Autologous stem cell transplantation in follicular lymphoma: a systematic review and meta-analysis","volume":"104","author":"Al Khabori M","year":"2012","unstructured":"Al Khabori M , De Almeida JR , Guyatt GH , Kuruvilla J , Crump M . Autologous stem cell transplantation in follicular lymphoma: a systematic review and meta-analysis . J. Natl Cancer Inst. 104 ( 1 ), 18 \u2013 28 ( 2012 ).","journal-title":"J. Natl Cancer Inst."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer-2018-0094","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T12:43:28Z","timestamp":1679229808000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2018-0094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.2217\/cer-2018-0094"],"URL":"https:\/\/doi.org\/10.2217\/cer-2018-0094","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4]]}}}